المؤلفون: L. A. Shpagina, O. S. Kotova, I. S. Shpagin, G. V. Kuznetsova, S. A. Karmanovskaya, L. A. Panacheva, E. V. Anikina, Л. А. Шпагина, О. С. Котова, И. С. Шпагин, Г. В. Кузнецова, С. А. Кармановская, Л. А. Паначева, Е. В. Аникина

المساهمون: Federal budget funds for the implementation of state task No.056-00034-21-00 were used, Исследование осуществлялось за счет средств федерального бюджета на исполнение государственного задания № 05600034-21-00

المصدر: PULMONOLOGIYA; Том 33, № 6 (2023); 739-749 ; Пульмонология; Том 33, № 6 (2023); 739-749 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: длительно действующие антихолинергические препараты, exacerbation, respiratory viral infection, inhaled corticosteroid, long-acting β2-agonist, longacting muscarinic antagonist, обострение, респираторная вирусная инфекция, ингаляционные глюко-кортикостероиды, длительно действующие β2-агонисты

وصف الملف: application/pdf

العلاقة: https://journal.pulmonology.ru/pulm/article/view/4372/3578Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4372/2183Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4372/2184Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4372/2185Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4372/2186Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4372/2187Test; GBD 2019 Chronic Respiratory Diseases Collaborators. Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the global burden of disease study 2019. EClinicalMedicine. 2023; 59: 101936. DOI:10.1016/j.eclinm.2023.101936.; Федеральная служба государственной статистики (Росстат). Российский статистический ежегодник: статистический сборник. М; 2022. Доступно на: https://rosstat.gov.ru/storage/mediabank/Ejegodnik_2022.pdfTest; Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 963–974. DOI:10.2147/COPD.S67283.; Быстрицкая Е.В., Биличенко Т.Н. Заболеваемость, инвалидность и смертность от болезней органов дыхания в Российской Федерации (2015–2019). Пульмонология. 2021; 31 (5): 551–561. DOI:10.18093/0869-0189-2021-31-5-551-561.; Brightling C., Greening N. Airway inflammation in COPD: progress to precision medicine. Eur. Respir. J. 2019; 54 (2): 1900651. DOI:10.1183/13993003.00651-2019.; Шпагина Л.А., Котова О.С., Сараскина Л.Е., Ермакова М.А. Особенности клеточно-молекулярных механизмов профессиональной хронической обструктивной болезни легких. Сибирское медицинское обозрение. 2018; 110 (2): 37–45. DOI:10.20333/2500136-2018-2-37-45.; Wu J.J., Xu H.R., Zhang Y.X. et al. The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a meta-analysis and system review. BMC Pulm. Med. 2020; 20 (1): 103. DOI:10.1186/s12890-020-1126-x.; Зыков К.А., Овчаренко С.И., Авдеев С.Н. и др. Фенотипические характеристики пациентов с хронической обструктивной болезнью легких, имеющих стаж курения, в Российской Федерации: данные исследования POPE-study. Пульмонология. 2020; 30 (1): 42–52. DOI:10.18093/0869-0189-2020-30-1-42-52.; Müllerová H., Marshall J., de Nigris E. et al. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis. Adv. Respir. Dis. 2022; 16: 17534666221113647. DOI:10.1177/17534666221113647.; Ghebre M.A., Pang P.H., Diver S. et al. Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. J. Allergy Clin. Immunol. 2018; 141 (6): 2027–2036.e12. DOI:10.1016/j.jaci.2018.04.013.; Hurst J.R., Han M.K., Singh B. et al. Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. Respir. Res. 2022; 23 (1): 213. DOI:10.1186/s12931-022-02123-5.; Visseaux B., Burdet C., Voiriot G. et al. Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016. PLoS One. 2017; 12 (7): e0180888. DOI:10.1371/journal.pone.0180888.; Jafarinejad H., Moghoofei M., Mostafaei S. et al. Worldwide prevalence of viral infection in AECOPD patients: a meta-analysis. Microb. Pathog. 2017; 113: 190–196. DOI:10.1016/j.micpath.2017.10.021.; Liao K.M., Chen Y.J., Shen C.W. et al. The influence of influenza virus infections in patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2022; 17: 2253–2261. DOI:10.2147/COPD.S378034.; Mahmud S.M.H., Al-Mustanjid M., Akter F. et al. Bioinformatics and system biology approach to identify the influences of SARS-CoV-2 infections to idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease patients. Brief. Bioinform. 2021; 22 (5): bbab115. DOI:10.1093/bib/bbab115.; Guo-Parke H., Linden D., Weldon S. et al. Mechanisms of virus-induced airway immunity dysfunction in the pathogenesis of COPD disease, progression, and exacerbation. Front. Immunol. 2020; 11: 1205. DOI:10.3389/fimmu.2020.01205.; D'Anna S.E., Maniscalco M., Cappello F. et al. Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease. Ann. Med. 2021; 53 (1): 135–150. DOI:10.1080/07853890.2020.1831050.; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Хроническая обструктивная болезнь легких: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022; 32 (3): 356–392. DOI:10.18093/0869-0189-2022-32-3-356-392.; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis and Management of COPD: 2023 COLD Report. Available at: https://goldcopd.org/2023-gold-report-2Test/ [Assecced: August 04, 2023].; Авдеев С.Н., Айсанов З.Р., Архипов В.В. и др. Назначение / отмена ингаляционных глюкокортикостероидов у больных хронической обструктивной болезнью легких как терапевтический континуум в реальной клинической практике. Пульмонология. 2023; 33 (1): 109–118. DOI:10.18093/0869-0189-2023-33-1-109-118.; Alcázar-Navarrete B, Jamart L, Sánchez-Covisa J. et al. Clinical characteristics, treatment persistence, and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: a retrospective analysis in Spain. Chest. 2022; 162 (5): 1017–1029. DOI:10.1016/j.chest.2022.06.033.; Jones P.W., Harding G., Berry P. et al. Development and first validation of the COPD Assessment Test. Eur. Respir. J. 2009; 34 (3): 648–654. DOI:10.1183/09031936.00102509.; Чучалин А.Г., Айсанов З.Р., Чикина С.Ю. и др. Федеральные клинические рекомендации Российского респираторного общества по использованию метода спирометрии. Пульмонология. 2014; (6): 11–24. DOI:10.18093/0869-0189-2014-0-6-11-24.; Graham B.L., Brusasco V., Burgos F. et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur. Respir. J. 2017; 49 (1): 1600016. DOI:10.1183/13993003.00016-2016.; ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166 (1): 111–117. DOI:10.1164/ajrccm.166.1.at1102.; Puhan M.A., Chandra D., Mosenifar Z. et al. The minimal important difference of exercise tests in severe COPD. Eur. Respir. J. 2011; 37 (4): 784–790. DOI:10.1183/09031936.00063810.; Шпагина Л.А., Котова О.С., Шпагин И.С. и др. Клинико-функциональные особенности хронической обструктивной болезни легких после вирус-ассоциированных обострений. Терапевтический архив. 2023; 95 (3): 217–222. DOI:10.26442/00403660.2023.03.202086.; Singh D., Papi A., Corradi M. et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016; 388 (10048): 963–973. DOI:10.1016/s0140-6736(16)31354-x.; Lipson D.A., Barnhart F., Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018; 378 (18): 1671–1680. DOI:10.1056/NEJMoa1713901.; Ferguson G.T., Rabe K.F., Martinez F.J. et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir. Med. 2018; 6 (10): 747–758. DOI:10.1016/S2213-2600(18)30327-8.; Halpin D.M.G., Kendall R., Shukla S. et al. Cost-effectiveness of single- versus multiple-inhaler triple therapy in a UK COPD population: the INTREPID trial. Int. J. Chron. Obstruct. Pulmon. Dis. 2022; 17: 2745–2755. DOI:10.2147/COPD.S370577.; Ferguson G.T., Brown N., Compton C. et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir. Res. 2020; 21 (1): 131. DOI:10.1186/s12931-020-01360-w.; David B., Bafadhel M., Koenderman L., De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021; 76 (2): 188–195. DOI:10.1136/thoraxjnl-2020-215167.; Насонов Е.Л., ред. Российские клинические рекомендации: Ревматология. М.: ГЭОТАР-Медиа; 2020.; De Sadeleer L.J., Hermans F., De Dycker E. et al. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J. Clin. Med. 2018; 8 (1): 14. DOI:10.3390/jcm8010014.; RECOVERY Collaborative Group; Horby P., Lim W.S. et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 2021; 384 (8): 693–704. DOI:10.1056/NEJMoa2021436.; Ponce-Gallegos M.A., Ramírez-Venegas A., Falfán-Valencia R. Th17 profile in COPD exacerbations. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 1857–1865. DOI:10.2147/COPD.S136592.; Su Y., Gu H., Weng D. et al. Association of serum levels of laminin, type IV collagen, procollagen III N-terminal peptide, and hyaluronic acid with the progression of interstitial lung disease. Medicine (Baltimore). 2017; 96 (18): e6617. DOI:10.1097/MD.0000000000006617.; https://journal.pulmonology.ru/pulm/article/view/4372Test

الإتاحة: https://doi.org/10.18093/0869-0189-2023-33-6-739-749Test
https://doi.org/10.1016/j.eclinm.2023.101936Test
https://doi.org/10.2147/COPD.S67283Test
https://doi.org/10.18093/0869-0189-2021-31-5-551-561Test
https://doi.org/10.1183/13993003.00651-2019Test
https://doi.org/10.20333/2500136-2018-2-37-45Test
https://doi.org/10.1186/s12890-020-1126-xTest
https://doi.org/10.18093/0869-0189-2020-30-1-42-52Test
https://doi.org/10.1177/17534666221113647Test
https://doi.org/10.1016/j.jaci.2018.04.013Test

المؤلفون: I. O. Marinkin, L. A. Shpagina, E. S. Lisova, I. S. Shpagin, O. S. Kotova, G. V. Kuznetsova, E. M. Loktin, S. A. Karmanovskaya, И. О. Маринкин, Л. А. Шпагина, Е. С. Лисова, И. С. Шпагин, О. С. Котова, Г. В. Кузнецова, Е. М. Локтин, С. А. Кармановская

المصدر: Medical Herald of the South of Russia; Том 13, № 4 (2022); 28-38 ; Медицинский вестник Юга России; Том 13, № 4 (2022); 28-38 ; 2618-7876 ; 2219-8075 ; 10.21886/2219-8075-2022-13-4

مصطلحات موضوعية: гиперплазия эндометрия, organic solvents, endometrial hyperplasia, органические растворители

وصف الملف: application/pdf

العلاقة: https://www.medicalherald.ru/jour/article/view/1707/937Test; Green MP, Harvey AJ, Finger BJ, Tarulli GA. Endocrine disrupting chemicals: Impacts on human fertility and fecundity during the peri-conception period. Environ Res. 2021;194:110694. https://doi.org/10.1016/j.envres.2020.110694Test; Yu Q, Zhang L, Hou K, Li J, Liu S, et al. Relationship between Air Pollutant Exposure and Gynecologic Cancer Risk. Int J Environ Res Public Health. 2021;18(10):5353. https://doi.org/10.3390/ijerph18105353Test; Liao Y, Peng S, He L, Wang Y, Li Y, et al. Methylmercury cytotoxicity and possible mechanisms in human trophoblastic HTR-8/SVneo cells. Ecotoxicol Environ Saf. 2021;207:111520. https://doi.org/10.1016/j.ecoenv.2020.111520Test; Фесенко М.А., Сивочалова О.В., Федорова Е.В. Профессиональная обусловленность заболеваний репродуктивной системы у работниц, занятых во вредных условиях труда. Анализ риска здоровью. 2017;3:92-100. https://doi.org/10.21668/health.risk/2017.3.11Test; Dumitrascu MC, Mares C, Petca RC, Sandru F, Popescu RI, et al. Carcinogenic effects of bisphenol A in breast and ovarian cancers. Oncol Lett. 2020;20(6):282. https://doi.org/10.3892/ol.2020.12145Test; Russo M, Newell JM, Budurlean L, Houser KR, Sheldon K, et al. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma. Cancer. 2020;126(12):2775-2783. https://doi.org/10.1002/cncr.32822Test; Doherty MT, Sanni OB, Coleman HG, Cardwell CR, McCluggage WG, et al. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PLoS One. 2020;15(4):e0232231. 10.1371/journal.pone.0232231; Raffone A, Travaglino A, Mascolo M, Insabato L, Zullo F. Predictive accuracy of hormone receptors in conservatively treated endometrial hyperplasia and early endometrioid carcinoma. Acta Obstet Gynecol Scand. 2020;99(1):140. https://doi.org/10.1111/aogs.13733Test; Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol. 2009;200(6):678.e1-6. https://doi.org/10.1016/j.ajog.2009.02.032Test; Wild CP, Weiderpass E, Stewart BW, eds. World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer; 2020.; Guha N, Loomis D, Grosse Y, Lauby-Secretan B, El Ghissassi F, et al. International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of trichloroethylene, tetrachloroethylene, some other chlorinated solvents, and their metabolites. Lancet Oncol. 2012;13(12):1192-3. https://doi.org/10.1016/s1470-2045Test(12)70485-0; IARC Monographs Vol 125 group. Carcinogenicity of some industrial chemical intermediates and solvents. Lancet Oncol. 2020;21(1):25-26. https://doi.org/10.1016/S1470-2045Test(19)30779-X; Cavallo D, Tranfo G, Ursini CL, Fresegna AM, Ciervo A, et al. Biomarkers of early genotoxicity and oxidative stress for occupational risk assessment of exposure to styrene in the fibreglass reinforced plastic industry. Toxicol Lett. 2018;298:53-59. https://doi.org/10.1016/j.toxlet.2018.06.006Test.; Varona-Uribe M, Ibáñez-Pinilla M, Briceno-Ayala L, Herrera D, Chuaire-Noack L, et al. Biomarkers of susceptibility and effect in car painters exposed to organic solvents. Colomb Med (Cali). 2020;51(1):e3646. https://doi.org/10.25100/cm.v51i1.3646Test; Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469-80. https://doi.org/10.1111/j.1464-5491.2006.01858.xTest; Bojanic D, Ljubojevic M, Krivokapic D, Gontarev S. Waist circumference, waist-to-hip ratio, and waist-to-height ratio reference percentiles for abdominal obesity among Macedonian adolescents. Nutr Hosp. 2020;37(4):786-793. https://doi.org/10.20960/nh.03006Test; Профессиональная патология: национальное руководство. Под ред. Измерова И.Ф. Москва: ГЭОТАР-Медиа; 2011.; https://www.medicalherald.ru/jour/article/view/1707Test

الإتاحة: https://doi.org/10.21886/2219-8075-2022-13-4-28-38Test
https://doi.org/10.21886/2219-8075-2022-13-4Test
https://doi.org/10.1016/j.envres.2020.110694Test
https://doi.org/10.3390/ijerph18105353Test
https://doi.org/10.1016/j.ecoenv.2020.111520Test
https://doi.org/10.21668/health.risk/2017.3.11Test
https://doi.org/10.3892/ol.2020.12145Test
https://doi.org/10.1002/cncr.32822Test
https://doi.org/10.1111/aogs.13733Test
https://doi.org/10.1016/j.ajog.2009.02.032Test

المؤلفون: L. A. Shpagina, O. S. Kotova, I. S. Shpagin, G. V. Kuznetsova, D. A. Gerasimenko, E. V. Anikina, Л. А. Шпагина, О. С. Котова, И. С. Шпагин, Г. В. Кузнецова, Д. А. Герасименко, Е. В. Аникина

المساهمون: The study was conducted at the expense of the federal budget according to the state assignment 056-00034-21-00., Исследование проводилось на средства федерального бюджета на исполнение государственного задания № 056-0003421-00.

المصدر: PULMONOLOGIYA; Том 32, № 2 (2022); 189-198 ; Пульмонология; Том 32, № 2 (2022); 189-198 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: обострение хронической обструктивной болезни легких, acute exacerbations of COPD

وصف الملف: application/pdf

العلاقة: https://journal.pulmonology.ru/pulm/article/view/3850/3197Test; Adeloye D., Chua S., Lee C. et al. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J. Glob. Health. 2015; 5 (2): 020415. DOI:10.7189/jogh.05-020415.; Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 963–974. DOI:10.2147/COPD.S67283.; INME. GBD Compare %7C Viz Hub. Available at: https://vizhub.healthdata.org/gbd-compareTest/ [Assecced: July 13, 2021].; Gerayeli FV, Milne S, Cheung C. et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021; 33: 100789. DOI:10.1016/j.eclinm.2021.100789.; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2021 Report. Available at: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdfTest [Assessed: July 13, 2021].; Айсанов З.Р., Авдеев С.Н., Архипов В.В. и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017; 27 (1): 13–20. DOI:10.18093/0869-0189-2017-27-1-13-20.; Suissa S., Dell’Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67 (11): 957–963. DOI:10.1136/thoraxjnl-2011-201518.; Naya I.P., Tombs L., Muellerova H. et al. Long-term outcomes following first short-term clinically important deterioration in COPD. Respir. Res. 2018; 19 (1): 222. DOI:10.1186/s12931-018-0928-3.; Kerkhof M., Voorham J., Dorinsky P. et al. Association between COPD exacerbations and lung function decline during maintenance therapy. Thorax. 2020; 75 (9): 744–753. DOI:10.1136/thoraxjnl-2019-214457.; Sato M., Chubachi S., Sasaki M. et al. Impact of mild exacerbation on COPD symptoms in a Japanese cohort. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11: 1269–1278. DOI:10.2147/COPD.S105454.; Westerik J.A.M., Metting E.I., van Boven J.F.M. et al. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respir. Res. 2017; 18 (1): 31. DOI:10.1186/s12931-017-0512-2.; Зыков К.А., Овчаренко С.И., Авдеев С.Н. и др. Фенотипические характеристики пациентов с хронической обструктивной болезнью легких, имеющих стаж курения, в Российской Федерации: данные исследования POPE-study. Пульмонология. 2020; 30 (1): 42–52. DOI:10.18093/0869-0189-2020-30-1-42-52.; Со А.К., Авдеев С.Н., Нуралиева Г.С. и др. Предикторы неблагоприятного исхода при обострении хронической обструктивной болезни легких. Пульмонология. 2018; 28 (4): 446–452. DOI:10.18093/0869-0189-2018-28-4-446-452.; Luo Z., Zhang W., Chen L., Xu N. Prognostic value of neutrophil: lymphocyte and platelet: Lymphocyte ratios for 28-day mortality of patients with AECOPD. Int. J. Gen. Med. 2021; 14: 2839–2848. DOI:10.2147/IJGM.S312045.; Crisafulli E., Ielpo A., Barbeta E. et al. Clinical variables predicting the risk of a hospital stay for longer than 7 days in patients with severe acute exacerbations of chronic obstructive pulmonary disease: a prospective study. Respir. Res. 2018; 19 (1): 261. DOI:10.1186/s12931-018-0951-4.; Brandsma C.A., Van den Berge M., Hackett T.L. et al. Recent advances in chronic obstructive pulmonary disease pathogenesis: from disease mechanisms to precision medicine. J. Pathol. 2020; 250 (5): 624–635. DOI:10.1002/path.5364.; Jones T.P.W., Brown J., Hurst J.R. et al. COPD exacerbation phenotypes in a real-world five year hospitalisation cohort. Respir. Med. 2020; 167: 105979. DOI:10.1016/j.rmed.2020.105979.; Jafarinejad H., Moghoofei M., Mostafaei S. et al. Worldwide prevalence of viral infection in AECOPD patients: a meta-analysis. Microb. Pathog. 2017; 113: 190–196. DOI:10.1016/j.micpath.2017.10.021.; Jones P.W., Harding G., Berry P. et al. Development and first validation of the COPD Assessment Test. Eur. Respir. J. 2009; 34 (3): 648–654. DOI:10.1183/09031936.00102509.; Чучалин А.Г., Айсанов З.Р., Чикина С.Ю. и др. Федеральные клинические рекомендации Российского респираторного общества по использованию метода спирометрии. Пульмонология. 2014; (6): 11–24. DOI:10.18093/0869-0189-2014-0-6-11-24.; Graham B.L., Brusasco V., Burgos F. et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur. Respir. J. 2017; 49 (1): 1600016. DOI:10.1183/13993003.00016-2016.; Pavord I.D., Lettis S., Anzueto A., Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir. Med. 2016; 4 (9): 731–741. DOI:10.1016/S2213-2600(16)30148-5.; Haldar P., Pavord I.D. Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J. Allergy Clin. Immunol. 2007; 119 (5): 1043–1052. DOI:10.1016/j.jaci.2007.02.042.; Gunasekaran K., Ahmad M., Rehman S. et al. Impact of a positive viral polymerase chain reaction on outcomes of chronic obstructive pulmonary disease (COPD) exacerbations. Int. J. Environ. Res. Public. Health. 2020; 17 (21): 8072. DOI:10.3390/ijerph17218072.; Wilkinson T.M.A., Hurst J.R., Perera W.R. et al. Eff of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest. 2006; 129 (2): 317–324. DOI:10.1378/chest.129.2.317.; Шпагина Л.А., Котова О.С., Сараскина Л.Е., Ермакова М.А. Особенности клеточно-молекулярных механизмов профессиональной хронической обструктивной болезни легких. Сибирское медицинское обозрение. 2018; 110 (2): 37–45. DOI:10.20333/2500136-2018-2-37-45.; Fonseca W., Lukacs N.W., Elesela S., Malinczak C.A. Role of ILC2 in viral-induced lung pathogenesis. Front. Immunol. 2021; 12: 675169. DOI:10.3389/fimmu.2021.675169.; Wronski S., Beinke S., Obernolte H. et al. Rhinovirus-induced human lung tissue responses mimic COPD and asthma gene signatures. Am. J. Respir. Cell. Mol. Biol. 2021: 65 (5): 544–554. DOI:10.1165/rcmb.2020-0337OC.; Jang J.G., Ahn J.H., Jin H.J. Incidence and prognostic factors of respiratory viral infections in severe acute exacerbation of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2021; 16: 1265–1273. DOI:10.2147/COPD.S306916.; https://journal.pulmonology.ru/pulm/article/view/3850Test

الإتاحة: https://doi.org/10.18093/0869-0189-2022-32-2-189-198Test
https://doi.org/10.7189/jogh.05-020415Test
https://doi.org/10.2147/COPD.S67283Test
https://doi.org/10.1016/j.eclinm.2021.100789Test
https://doi.org/10.18093/0869-0189-2017-27-1-13-20Test
https://doi.org/10.1136/thoraxjnl-2011-201518Test
https://doi.org/10.1186/s12931-018-0928-3Test
https://doi.org/10.1136/thoraxjnl-2019-214457Test
https://doi.org/10.2147/COPD.S105454Test
https://doi.org/10.1186/s12931-017-0512-2Test

المؤلفون: L. A. Shpagina, O. S. Kotova, I. S. Shpagin, D. A. Gerasimenko, G. V. Kuznetsova, S. A. Karmanovskaya, E. M. Loktin, A. A. Rukavitsyna, E. V. Anikina, N. V. Kamneva, K. V. Likhenko-Logvinenko, Л. А. Шпагина, О. С. Котова, И. С. Шпагин, Д. А. Герасименко, Г. В. Кузнецова, С. А. Кармановская, Е. М. Локтин, А. А. Рукавицына, Е. В. Аникина, Н. В. Камнева, К. В. Лихенко-Логвиненко

المساهمون: The article was written within the framework of the state assignment 056-00034-21-00, Статья написана в рамках государственного задания 056-00034-21-00

المصدر: Meditsinskiy sovet = Medical Council; № 18 (2022); 30-39 ; Медицинский Совет; № 18 (2022); 30-39 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: фиброз, acute exacerbations of chronic obstructive pulmonary disease, respiratory viruses, inflammation, fibrosis, обострение хронической обструктивной болезни легких, респираторные вирусы, воспаление

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7117/6389Test; MacDonald M.I., Osadnik C.R., Bulfin L., Leahy E., Leong P., Shafuddin E. et al. MULTI-PHACET: multidimensional clinical phenotyping of hospitalised acute COPD exacerbations. ERJ Open Res. 2021;7(3):00198–2021. https://doi.org/10.1183/23120541.00198-2021Test.; Jafarinejad H., Moghoofei M., Mostafaei S., Salimian J., Azimzadeh Jamalkandi S., Ahmadi A. Worldwide prevalence of viral infection in AECOPD patients: A meta-analysis. Microb Pathog. 2017;113:190–196. https://doi.org/10.1016/j.micpath.2017.10.021Test.; Jang J.G., Ahn J.H., Jin H.J. Incidence and prognostic factors of respiratory viral infections in severe acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021;16:1265–1273. https://doi.org/10.2147/COPD.S306916Test.; Lee H.W., Sim Y.S., Jung J.Y., Seo H., Park J.W., Min K.H. et al. A multicenter study to identify the respiratory pathogens associated with exacerbation of chronic obstructive pulmonary disease in Korea. Tuberc Respir Dis (Seoul). 2022;85(1):37–46. https://doi.org/10.4046/trd.2021.0080Test.; Polverino F., Kheradmand F. COVID-19, COPD, and AECOPD: Immunological, epidemiological, and clinical aspects. Front Med (Lausanne). 2021;7:627278. https://doi.org/10.3389/fmed.2020.627278Test.; Huebner S.T., Henny S., Giezendanner S., Brack T., Brutsche M., Chhajed P. et al. Prediction of acute COPD exacerbation in the Swiss multicenter COPD cohort study (TOPDOCS) by clinical parameters, medication use, and immunological biomarkers. Respiration. 2022;101(5):441–454. https://doi.org/10.1159/000520196Test.; Suissa S., Dell’Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963. https://doi.org/10.1136/thoraxjnl-2011-201518Test.; Зыков К.А., Овчаренко С.И., Авдеев С.Н., Жестков А.В., Илькович М.М., Невзорова В.А. и др. Фенотипические характеристики пациентов с хронической обструктивной болезнью легких, имеющих стаж курения, в Российской Федерации: данные исследования POPE-study. Пульмонология. 2020;30(1):42–52. https://doi.org/10.18093/0869-0189-2020-30-1-42-52Test.; Rhodes K., Jenkins M., de Nigris E., Aurivillius M., Ouwens M. Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study. BMC Med Res Methodol. 2022;22(1):150. https://doi.org/10.1186/s12874-022-01616-7Test.; Со А.К., Авдеев С.Н., Нуралиева Г.С., Гайнитдинова В.В., Чучалин А.Г. Предикторы неблагоприятного исхода при обострении хронической обструктивной болезни легких. Пульмонология. 2018;28(4):446–452. https://doi.org/10.18093/0869-0189-2018-28-4-446-452Test.; Luo Z., Zhang W., Chen L., Xu N. Prognostic Value of Neutrophil:Lymphocyte and Platelet:Lymphocyte Ratios for 28-Day Mortality of Patients with AECOPD. Int J Gen Med. 2021;14:2839–2848. https://doi.org/10.2147/IJGM.S312045Test.; Cao Y., Xing Z., Long H., Huang Y., Zeng P., Janssens J.P., Guo Y. Predictors of mortality in COPD exacerbation cases presenting to the respiratory intensive care unit. Respir Res. 2021;22(1):77. https://doi.org/10.1186/s12931-021-01657-4Test.; Быстрицкая Е.В., Биличенко Т.Н. Заболеваемость, инвалидность и смертность от болезней органов дыхания в Российской Федерации (2015–2019). Пульмонология. 2021;31(5):551–561. https://doi.org/10.18093/0869-0189-2021-31-5-551-561Test.; Jones T.P.W., Brown J., Hurst J.R., Vancheeswaran R., Brill S. COPD exacerbation phenotypes in a real-world five year hospitalisation cohort. Respir Med. 2020;167:105979. https://doi.org/10.1016/j.rmed.2020.105979Test.; Ritchie A.I., Wedzicha J.A. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med. 2020;41(3):421–438. https://doi.org/10.1016/j.ccm.2020.06.007Test.; Li T., Gao L., Ma H.X., Wei Y.Y., Liu Y.H., Qin K.R. et al. Clinical value of IL-13 and ECP in the serum and sputum of eosinophilic AECOPD patients. Exp Biol Med (Maywood). 2020;245(14):1290–1298. https://doi.org/10.1177/1535370220931765Test.; Ji S., Dai M.Y., Huang Y., Ren X.C., Jiang M.L., Qiao J.P. et al. Influenza a virus triggers acute exacerbation of chronic obstructive pulmonary disease by increasing proinflammatory cytokines secretion via NLRP3 inflammasome activation. J Inflamm (Lond). 2022;19(1):8. https://doi.org/10.1186/s12950-022-00305-yTest.; Wronski S., Beinke S., Obernolte H., Belyaev N.N., Saunders K.A., Lennon M.G. et al. Rhinovirus-induced human lung tissue responses mimic chronic obstructive pulmonary disease and asthma gene signatures. Am J Respir Cell Mol Biol. 2021;65(5):544–554. https://doi.org/10.1165/rcmb.2020-0337OCTest.; Thulborn S.J., Mistry V., Brightling C.E., Moffitt K.L., Ribeiro D., Bafadhel M. Neutrophil elastase as a biomarker for bacterial infection in COPD. Respir Res. 2019;20(1):170. https://doi.org/10.1186/s12931-019-1145-4Test.; Chakrabarti A., Mar J.S., Choy D.F., Cao Y., Rathore N., Yang X. et al. High serum granulocyte-colony stimulating factor characterises neutrophilic COPD exacerbations associated with dysbiosis. ERJ Open Res. 2021;7(3):00836–2020. https://doi.org/10.1183/23120541.00836-2020Test.; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Лещенко И.В., Овчаренко С.И., Шмелев Е.И. Хроническая обструктивная болезнь легких: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022;32(3):356–392. https://doi.org/10.18093/0869-0189-2022-32-3-356-392Test.; Weissler J.C., Adams T.N. Eosinophilic chronic obstructive pulmonary disease. Lung. 2021;199(6):589–595. https://doi.org/10.1007/s00408-021-00492-0Test.; Chen X.R., Wang D.X. Serum MCP-1 and NGAL play an important role in the acute inflammatory event of chronic obstructive pulmonary disease. COPD. 2021;18(4):425–431. https://doi.org/10.1080/15412555.2021.1954151Test.; Chanda D., Otoupalova E., Smith S.R., Volckaert T., De Langhe S.P., Thannickal V.J. Developmental pathways in the pathogenesis of lung fibrosis. Mol Aspects Med. 2019;65:56–69. https://doi.org/10.1016/j.mam.2018.08.004Test.; Zhang Y., Li Y., Ye Z., Ma H. Expression of matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and changes in alveolar septa in patients with chronic obstructive pulmonary disease. Med Sci Monit. 2020;26:e925278. https://doi.org/10.12659/MSM.925278Test.; Johansen M.D., Mahbub R.M., Idrees S., Nguyen D.H., Miemczyk S., Pathinayake P. et al. Increased SARS-CoV-2 infection, protease and inflammatory responses in COPD primary bronchial epithelial cells defined with single cell RNA-sequencing. Am J Respir Crit Care Med. 2022. https://doi.org/10.1164/rccm.202108-1901OCTest.; Baldi B.G., Fabro A.T., Franco A.C., Machado M.H.C., Prudente R.A., Franco E.T. et al. Clinical, radiological, and transbronchial biopsy findings in patients with long COVID-19: a case series. J Bras Pneumol. 2022;48(3):e20210438. https://doi.org/10.36416/1806-3756/e20210438Test.; Bafadhel M., Peterson S., De Blas M.A., Calverley P.M., Rennard S.I., Richter K., Fagerås M. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126. https://doi.org/10.1016/S2213-2600Test(18)30006-7.; Rana R., Huang T., Koukos G., Fletcher E.K., Turner S.E., Shearer A. et al. Noncanonical matrix metalloprotease 1-protease-activated receptor 1 signaling drives progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2018;38(6):1368–1380. https://doi.org/10.1161/ATVBAHA.118.310967Test.; https://www.med-sovet.pro/jour/article/view/7117Test

الإتاحة: https://doi.org/10.21518/2079-701X-2022-16-18-30-39Test
https://doi.org/10.1183/23120541.00198-2021Test
https://doi.org/10.1016/j.micpath.2017.10.021Test
https://doi.org/10.2147/COPD.S306916Test
https://doi.org/10.4046/trd.2021.0080Test
https://doi.org/10.3389/fmed.2020.627278Test
https://doi.org/10.1159/000520196Test
https://doi.org/10.1136/thoraxjnl-2011-201518Test
https://doi.org/10.18093/0869-0189-2020-30-1-42-52Test
https://doi.org/10.1186/s12874-022-01616-7Test

المؤلفون: L. A. Shpagina, O. S. Kotova, I. S. Sphagin, N. P. Kareva, L. Yu. Zyubina, L. A. Panacheva, L. E. Saraskina, T. N. Surovenko, Л. А. Шпагина, О. С. Котова, И. С. Шпагин, Н. П. Карева, Л. Ю. Зюбина, Л. А. Паначева, Л. Е. Сараскина, Т. Н. Суровенко

المصدر: PULMONOLOGIYA; Том 28, № 2 (2018); 135-146 ; Пульмонология; Том 28, № 2 (2018); 135-146 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2018-28-2

مصطلحات موضوعية: анемия, chronic obstructive pulmonary disease, phenotype, anemia, хроническая обструктивная болезнь легких, фенотип

وصف الملف: application/pdf

العلاقة: https://journal.pulmonology.ru/pulm/article/view/980/816Test; Chetty U., McLean G., Morrison D. et al. Chronic obstructive pulmonary disease and comorbidities: a large cross-sectional study in primary care. Br. J. Gen. Pract. 2017; 67 (658): 321–328. DOI:10.3399/bjgp17X690605.; Miller J., Edwards L.D., Agustí A. et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir. Med. 2013; 107 (9): 1376–1384. DOI:10.1016/j.rmed.2013.05.001.; GOLD 2018. Global Strategy for the Diagnosis, Management and Prevention of COPD. Available at: http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdfTest/ [Accessed 23 March, 2018].; Айсанов З.Р., Авдеев С.Н., Архипов В.В. и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017; 27 (1): 13–20. DOI:10.18093/0869-0189-2017-27-1-13-20.; Авдеев С.Н. Хроническая обструктивная болезнь легких как системное заболевание. Пульмонология. 2007; (2): 104–117.; Barnes P.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2016;138 (1): 16–27. DOI:10.1016/j.jaci.2016.05.011.; Suchdev P.S., Williams A.M., Mei Z. et al. Assessment of iron status in settings of inflammation: challenges and potential approaches. Am. J. Clin. Nutr. 2017; 106 (Suppl. 6): 1626–1633. DOI:10.3945/ajcn.117.155937.; Tandara L., Grubisic T.Z., Ivan G. et al. Systemic inflammation up-regulates serum hepcidin in exacerbations and stabile chronic obstructive pulmonary disease. Clin. Biochem. 2015; 48 (18): 1252–1257. DOI:10.1016/j.clinbiochem.2015.07.010.; Robalo Nunes A., Tátá M. The impact of anaemia and iron deficiency in chronic obstructive pulmonary disease: A clinical overview. Rev. Port. Pneumol. 2017; 23 (3): 146–155. DOI:10.1016/j.rppnen.2016.12.005.; Cluzeau T., McGraw K.L., Irvine B. et al. Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes. Haematologica. 2017; 102 (12): 2015–2020. DOI:10.3324/haematol.2016.158857.; Sharma R.K., Chakrabarti S. Anaemia secondary to erythropoietin resistance: important predictor of adverse outcomes in chronic obstructive pulmonary disease. Postgrad. Med. J. 2016; 1093 (92): 636–640. DOI:10.1136/postgradmedj-2015-133814.; Comeche Casanova L., Echave-Sustaeta J.M., García Luján R. et al. Prevalence of anaemia associated with chronic obstructive pulmonary disease. Study of associated variables. Arch. Bronconeumol. 2013; 49 (9): 383–387. DOI:10.1016/j.arbres.2013.04.007.; Markoulaki D., Kostikas K., Papatheodorou G. et al. Hemoglobin, erythropoietin and systemic inflammation in exacerbations of chronic obstructive pulmonary disease. Eur. J. Intern. Med. 2011; 22 (1): 103–107. DOI:10.1016/j.ejim.2010.07.010.; Horadagoda C., Dinihan T., Roberts M. et al. Body composition and micronutrient deficiencies in patients with an acute exacerbation of chronic obstructive pulmonary disease. Intern. Med. J. 2017; 47 (9): 1057–1063. DOI:10.1111/imj.13453.; Fimognari F.L., Loffredo L., Di Simone S. et al. Hyperhomocysteinaemia and poor vitamin B status in chronic obstructive pulmonary disease. Nutr. Metab. Cardiovasc. Dis. 2009; 19 (9): 654–659. DOI:10.1016/j.numecd.2008.12.006.; Cote C., Zilberberg M.D., Mody S.H. et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur. Respir. J. 2007; 29 (5): 923–929. DOI:10.1183/09031936.00137106.; Boutou A.K., Stanopoulos I., Pitsiou G.G. et al. Anemia of chronic disease in chronic obstructive pulmonary disease: a case-control study of cardiopulmonary exercise responses. Respiration. 2011; 82 (3): 237–245. DOI:10.1159/000326899.; Кузубова Н., Привалова Е., Титова О. и др. Симптоматический эритроцитоз и анемия при хронической обструктивной болезни легких. Врач. 2013; (2): 29–31.; Gadre S.K., Jhand A.S., Abuqayyas S. et al. Effect of anemia on mortality in mechanically ventilated patients with chronic obstructive pulmonary disease. J. Intensive Care Med. 2017; 885066617739561. DOI:10.1177/0885066617739561.; Акрамова Э.Г., Стручков П.В. Влияние анемии на функциональное состояние сердечнососудистой системы у больных хронической обструктивной болезнью легких. Пульмонология. 2012; (5): 28–32. DOI:10.18093/0869-0189-2012-0-5-28-32.; Ferrari M., Manea L., Anton K. et al. Anemia and hemoglobin serum levels are associated with exercise capacity and quality of life in chronic obstructive pulmonary disease. BMC Pulm. Med. 2015; 15: 58. DOI:10.1186/s12890-015-0050-y.; Будневский А.В., Провоторов В.М., Ульянова М.И. Хроническая обструктивная болезнь легких и анемия: клинические проявления и тактика лечения. Клиническая медицина. 2016; 94 (9): 677–683. Доступно по: https://cyberleninka.ru/article/v/hronicheskaya-obstruktivnaya-bolezn-legkih-i-anemiya-klinicheskie-proyavleniya-i-taktika-lecheniyaTest/; Oh Y.M., Park J.H., Kim E.K. et al. Anemia as a clinical marker of stable chronic obstructive pulmonary disease in the Korean obstructive lung disease cohort. J. Thorac. Dis. 2017; 9 (12): 5008–5016. DOI:10.21037/jtd.2017.10.140.; Lau C.S., Siracuse B.L., Chamberlain R.S. Readmission after COPD exacerbation scale: determining 30-day readmission risk for COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 1891–1902. DOI:10.2147/COPD.S136768.; Cazzola M., Calzetta L., Rogliani P. et al. The challenges of precision medicine in COPD. Mol. Diagn. Ther. 2017; 21 (4): 345–355. DOI:10.1007/s40291-017-0266-z.; Чучалин А.Г., Айсанов З.Р., Чикина С.Ю. и др. Федеральные клинические рекомендации Российского респираторного общества по использованию метода спирометрии. Пульмонология. 2014; (6): 11–24. DOI:10.18093/0869-0189-2014-0-6-11-24.; Agustí A., Edwards L.D., Rennard S.I. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012; 7 (5): e37483. DOI:10.1371/journal.pone.0037483.; Olenscki Gilli S.C., Pericole F.V., Benites B.D. et al. Cytokine polymorphisms in sickle cell disease and the relationship with cytokine expression. Exp. Hematol. 2016; 44 (7): 583–589. DOI:10.1016/j.exphem.2016.03.008.; Platzbecker U., Germing U., Götze K.S. et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicenter a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017; 18 (10): 1338–1347. DOI:10.1016/S1470-2045(17)30615-0; https://journal.pulmonology.ru/pulm/article/view/980Test

الإتاحة: https://doi.org/10.18093/0869-0189-2018-28-2-135-146Test
https://doi.org/10.18093/0869-0189-2018-28-2Test
https://doi.org/10.3399/bjgp17X690605Test
https://doi.org/10.1016/j.rmed.2013.05.001Test
https://doi.org/10.18093/0869-0189-2017-27-1-13-20Test
https://doi.org/10.1016/j.jaci.2016.05.011Test
https://doi.org/10.3945/ajcn.117.155937Test
https://doi.org/10.1016/j.clinbiochem.2015.07.010Test
https://doi.org/10.1016/j.rppnen.2016.12.005Test
https://doi.org/10.3324/haematol.2016.158857Test

المؤلفون: L. A. Shpagina, I. S. Shpagin, O. S. Kotova, T. I. Pospelova, O. N. Gerasimenko, Л. А. Шпагина, И. С. Шпагин, О. С. Котова, Т. И. Поспелова, О. Н. Герасименко

المصدر: PULMONOLOGIYA; Том 26, № 6 (2016); 681-693 ; Пульмонология; Том 26, № 6 (2016); 681-693 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2016-26-6

مصطلحات موضوعية: лечение, phenotype, treatment, фенотип

وصف الملف: application/pdf

العلاقة: https://journal.pulmonology.ru/pulm/article/view/791/671Test; Чучалин А.Г., Айсанов З.Р., Авдеев С.Н. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких [Электронный ресурс]. http://www.pulmonology.ru/publications/guide.phpTest (дата обращения: 20.07.2016).; Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2016). Available at: http://www.goldcopd.org/guidelinesglobalstrategyfordiagnosismanagement.htmlTest. 2016. Accessed July 20, 2016.; Kornmann O., Dahl R., Centanni S. et al. Oncedaily indacaterol versus twicedaily salmeterol for COPD: a placebo controlled comparison. Eur. Respir. J. 2011; 37 (2): 273– 279. DOI:10.1183/09031936.00045810.; Marin J.M., Beeh K.M., Clemens A. et al. Early bronchodilator action of glycopyrronium versus tiotropium in moderatetosevere COPD patients: a crossover blinded randomized study (Symptoms and pulmonary function in the moRnING). Int. J. Chron. Obstruct. Pulm. Dis. 2016; 11: 1425–134.; Wedzicha J.A., Singh D., Vestbo J. et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir. Med. 2014; 108 (8): 1153–1162. DOI: http://dx.doi.org/10.1016/j.rmed.2014.05.013Test.; Agusti A., Bel E., Thomas M. et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur. Respir. J. 2016; 47 (2): 410–419. DOI:10.1183/13993003.013592015.; Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/longacting β2 agonist efficacy in COPD. Thorax. 2016; 71 (2): 118–125.; Suissa S., Dell'Aniello S., Ernst P. Longterm natural history of chronic obstructive pulmonary disease: severe exacer bations and mortality. Thorax. 2012; 67 (11): 957–963. DOI:10.1136/thoraxjnl2011201518.; Miravitlles M., SolerCataluna J.J., Calle M., Soriano J.B. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice Eur. Respir. J. 2013; 41 (6): 1252–1256.; Rennard S.I., Calverley P.M., Goehring U.M. et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir. Res. 2011; 12: 18.; Чучалин А.Г., Шпагина Л.А., Васильева О.С. и др. Профессиональная хроническая обструктивная болезнь легких. Профессиональные заболевания органов дыхания: Национальное руководство. M.: ГЭОТАР; 2015: 293–338.; Rodríguez E., Ferrer J., Zock J.P. et al. Lifetime occupational exposure to dusts, gases and fumes is associated with bronchitis symptoms and higher diffusion capacity in COPD patients. PLoS One. 2014; 9 (2): e88426.; Brüske I., Thiering E., Heinrich J. et al. Biopersistent granular dust and chronic obstructive pulmonary disease: a systematic review and metaanalysis. PLoS One. 2013; 8 (11): e80977.; Шпагина Л.А., Воевода М.И., Котова О.С. и др. Профессиональная хроническая обструктивная болезнь легких с позиций молекулярногенетических исследований. Бюллетень физиологии и патологии дыхания. 2013; (49): 8–15.; Miller J., Edwards L.D., Agustí A. et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir. Med. 2013; 107 (9): 1376–1384.; Shrikrishna D., Astin R., Kemp P.R., Hopkinson N.S. Reninangiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin. Sci. (Lond). 2012; 123 (8): 487–498.; Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. TheTask Force for the management of arterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2013; 31 (7): 1281–1357.; Miller M.R., Hankinson J., Brusasco V. et al. ATS/ERS Task Force. Standardisation of spirometry. Eur. Respir. J. 2005; 26 (2): 319–338.; Rossi A., Zanardi E., Poletti V., Cazzola M. Clinical role of dual bronchodilation with an indacaterolglycopyrronium combination in the management of COPD: its impact on patientrelated outcomes and quality of life. Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 1383–1392.; Beier J., Kirsten A.M., Mróz R. et al. Efficacy and safety of; aclidinium bromide compared with placebo and tiotropium in patients with moderatetosevere chronic obstructive pulmonary disease: results from a 6week, randomized, controlled Phase IIIb study. COPD. 2013; 10 (4): 511–522.; https://journal.pulmonology.ru/pulm/article/view/791Test

الإتاحة: https://doi.org/10.18093/08690189201626681693Test
https://doi.org/10.18093/0869-0189-2016-26-6Test
https://doi.org/10.1183/09031936.00045810Test
https://doi.org/10.1016/j.rmed.2014.05.013Test
https://doi.org/10.1183/13993003.013592015Test
https://doi.org/10.1136/thoraxjnl2011201518Test
https://journal.pulmonology.ru/pulm/article/view/791Test

المؤلفون: L. A. Shpagina, M. I. Voevoda, S. V. Bobrov, V. N. Maksimov, P. S. Orlov, I. S. Shpagin, O. N. Gerasimenko, T I. Pospelova, Л. А. Шпагина, М. И. Воевода, С. В. Бобров, В. Н. Максимов, П. С. Орлов, И. С. Шпагин, О. Н. Герасименко, Т. И. Поспелова

المصدر: PULMONOLOGIYA; № 4 (2012); 78-84 ; Пульмонология; № 4 (2012); 78-84 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2012-0-4

مصطلحات موضوعية: бронхообструктивный синдром, industrial pollutants, occupational bronchitis, bronchial obstructive syndrome, профессиональный бронхит, промышленный аэрозоль

وصف الملف: application/pdf

العلاقة: https://journal.pulmonology.ru/pulm/article/view/105/103Test; Fletcher C.M. Disability and mortality from chronic bronchitis in relation to dust exposure. Arch. Industr. Hlth 1958; 18: 368–373.; Mapp C.E. Occupational lung disorders. Eur. Respir. Monogr. 1999; 11: 113–207.; Васильева О.С. Хроническая обструктивная болезнь легких и профессиональные факторы. Пульмонология 2007; 6: 5–11.; Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2009). Gig Harbor, WA: Medical Communications Resources, Inc; 2009.; Чучалин А.Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания. Пульмонология 2008; 2: 5–14.; Castaldi P.J., Cho M.H., Cohn M. et al. The COPD genetic association compendium: a comprehensive online database of COPD genetic associations. Hum. Mol. Genet. 2010; 19 (3): 526–534.; Корытина Г.Ф. Mолекулярно-генетический анализ наследственной предрасположенности к хроническим заболеваниям органов дыхания: Автореф. дис. … д-ра биол. наук. Уфа; 2012.; Faramawy M.M., Mohammed T.O., Hossaini A.M. et al. Genetic polymorphism of GSTT1 and GSTM1 and susceptibility to chronic obstructive pulmonary disease (COPD). J. Crit. Care 2009; 24 (3): 7–10.; Cheng S.L., Yu C.J., Chen C.J. et al. Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD. Eur. Respir. J. 2004; 23 (6): 818–824.; Van Diemen C.C., Postma D.S., Aulchenko Y.S. et al. Novel strategy to identify genetic risk factors for COPD severity: a genetic isolate. Eur. Respir. J. 2010; 35 (4): 768–775.; Кузьмина Л.П. Биохимические и молекулярно-генетические механизмы развития профессиональной бронхолегочной патологии. Пульмонология 2008; 4: 107–110.; Castaldi P.J., Cho M.H., Cohn M. et al. The COPD genetic association compendium: a comprehensive online database of COPD genetic associations. Hum. Mol. Genet. 2010; 19 (3): 526–534; So/rheim I.C., DeMeo D.L., Washko G. et al. Polymorphisms in the superoxide dismutase-3 gene are associated with emphysema in COPD. COPD 2010; 7 (4): 262–268.; Корытина Г.Ф., Ахмадишина Л.З., Целоусова О.С. и др. Анализ полиморфных вариантов генов ферментов антиоксидантной защиты и их связь с развитием хронической обструктивной болезни легких у жителей республики Башкортостан. Генетика 2009; 45 (7): 967–976.; Pillai S.G., Ge D., Zhu G. et al. ICGN Investigators. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 2009; 5 (3): e1000421.; Van Durme Y.M., Eijgelsheim M., Joos G.F. et al. Hedgehoginteracting protein is a COPD susceptibility gene: the Rotterdam Study. Eur. Respir. J. 2010; 36 (1): 89–95.; Ferreira M.A., Matheson M.C., Duffy D.L. et al. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet 2011; 378 (9795): 1006–1014.; Wilk J.B., Walter R.E., Laramie J.M. et al. Framingham Heart Study genome-wide association: results for pulmonary function measures. BMC Med. Genet. 2007; 8 (Suppl. 1): S8.; Zhang J., Summah H., Zhu Y.G. et al. Nicotinic acetylcholine receptor variants associated with susceptibility to chronic obstructive pulmonary disease: a meta-analysis. Respir. Res. 2011; 12: 158.; Budulac S.E., Vonk J.M., Postma D.S. et al. Nicotinic acetylcholine receptor variants are related to smoking habits, but not directly to COPD. PLoS One 2012; 7 (3): e33386.; https://journal.pulmonology.ru/pulm/article/view/105Test

الإتاحة: https://doi.org/10.18093/0869-0189-2012-0-4-78-84Test
https://doi.org/10.18093/0869-0189-2012-0-4Test
https://journal.pulmonology.ru/pulm/article/view/105Test